SPINK1 staining is present with lower incidence (approximately 10%) in prostate cancer, where it was reported as a marker for a particularly aggressive molecular subtype associated with poor progression free and recurrence free survival [32, 33], although subsequent studies using different cohorts have not uniformly confirmed the association with clinical outcome [34-36]. The gene discussed is SPINK1; the disease is prostate cancer.